HPV-18E6 derived immunogenic peptide vaccine (NCI)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameHPV-18E6 derived immunogenic peptide vaccine (NCI)
Drug Alias NameHPV-18E6 derived immunogenic peptide vaccine (National Cancer Institute)
ClassificationVaccines > Development/production technology > Inactivated vaccine > Subunit vaccineBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsUterine Cervical Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Institutes Of HealthNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsUterine Cervical Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A